J Cancer 2024; 15(11):3466-3480. doi:10.7150/jca.94452 This issue Cite

Research Paper

Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase

Madiha Kanwal1, Ingrid Polakova1, Mark Olsen2, Murtaza Khan Kasi1, Ruth Tachezy1, Michal Smahel1✉

1. Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic.
2. Department of Pharmaceutical Sciences, College of Pharmacy - Glendale, Midwestern University, Glendale, AZ, USA.

Citation:
Kanwal M, Polakova I, Olsen M, Kasi MK, Tachezy R, Smahel M. Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. J Cancer 2024; 15(11):3466-3480. doi:10.7150/jca.94452. https://www.jcancer.org/v15p3466.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: Cancer development involves alterations in key cellular pathways, with aspartate β-hydroxylase (ASPH) emerging as an important player in tumorigenesis. ASPH is upregulated in various cancer types, where it promotes cancer progression mainly by regulating the Notch1 and SRC pathways.

Methods: This study explored the responses of various human cervical, pharyngeal, and breast tumor cell lines to second- and third-generation ASPH inhibitors (MO-I-1151 and MO-I-1182) using proliferation, migration, and invasion assays; western blotting; and cell cycle analysis.

Results: ASPH inhibition significantly reduced cell proliferation, migration, and invasion and disrupted both the canonical and noncanonical Notch1 pathways. The noncanonical pathway was particularly mediated by AKT signaling. Cell cycle analysis revealed a marked reduction in cyclin D1 expression, further confirming the inhibitory effect of ASPH inhibitors on cell proliferation. Additional analysis revealed G0/G1 arrest and restricted progression into S phase, highlighting the regulatory impact of ASPH inhibitors on the cell cycle. Furthermore, ASPH inhibition induced distinctive alterations in nuclear morphology. The high heterogeneity in the responses of individual tumor cell lines to ASPH inhibitors, both quantitatively and qualitatively, underscores the complex network of mechanisms that are regulated by ASPH and influence the efficacy of ASPH inhibition. The effects of ASPH inhibitors on Notch1 pathway activity, cyclin D1 expression, and nuclear morphology contribute to the understanding of the multifaceted effects of these inhibitors on cancer cell behavior.

Conclusion: This study not only suggests that ASPH inhibitors are effective against tumor cell progression, in part through the induction of cell cycle arrest, but also highlights the diverse and heterogeneous effects of these inhibitors on the behavior of tumor cells of different origins.

Keywords: ASPH inhibitors, tumorigenesis, Notch pathway, AKT signaling, heterogeneity, cell cycle


Citation styles

APA
Kanwal, M., Polakova, I., Olsen, M., Kasi, M.K., Tachezy, R., Smahel, M. (2024). Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. Journal of Cancer, 15(11), 3466-3480. https://doi.org/10.7150/jca.94452.

ACS
Kanwal, M.; Polakova, I.; Olsen, M.; Kasi, M.K.; Tachezy, R.; Smahel, M. Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. J. Cancer 2024, 15 (11), 3466-3480. DOI: 10.7150/jca.94452.

NLM
Kanwal M, Polakova I, Olsen M, Kasi MK, Tachezy R, Smahel M. Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. J Cancer 2024; 15(11):3466-3480. doi:10.7150/jca.94452. https://www.jcancer.org/v15p3466.htm

CSE
Kanwal M, Polakova I, Olsen M, Kasi MK, Tachezy R, Smahel M. 2024. Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. J Cancer. 15(11):3466-3480.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image